Between 2022 and 2023, there were 32,276 young people with type 1 diabetes and 1,245 with type 2 across England and Wales. The most affected were the ones with white ethnicity. This statistic shows the share of young people under the age of 24, with type 1 and 2 diabetes in England and Wales from 2022 to 2023, by ethnicity.

United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Between 2023 and 2024, over sixteen percent of all those registered with type 2 diabetes in England were Asian or Asian British. This statistic displays the share of individuals registered with diabetes in England in 2023/24, by ethnicity.

United Kingdom UK: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 4.280 % in 2017. United Kingdom UK: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 4.280 % from Dec 2017 (Median) to 2017, with 1 observations. United Kingdom UK: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Kingdom – Table UK.World Bank.WDI: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

This forecast illustrates the number of diabetes type 2 cases in the United States from 2007 to 2020. In 2020, some 28.2 million adults among the U.S. population are expected to live with the type 2 diabetes.

Germany DE: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 6.900 % in 2021. This records an increase from the previous number of 5.300 % for 2011. Germany DE: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 6.100 % from Dec 2011 (Median) to 2021, with 2 observations. The data reached an all-time high of 6.900 % in 2021 and a record low of 5.300 % in 2011. Germany DE: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Germany – Table DE.World Bank.WDI: Social: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes. It is calculated by adjusting to a standard population age-structure.;International Diabetes Federation, Diabetes Atlas.;Weighted average;

Diabetes prevalence in Massachusetts has been steadily increasing.

Cameroon CM: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 5.500 % in 2021. This records a decrease from the previous number of 6.100 % for 2011. Cameroon CM: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 5.500 % from Dec 2000 (Median) to 2021, with 3 observations. The data reached an all-time high of 6.100 % in 2011 and a record low of 0.000 % in 2000. Cameroon CM: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Cameroon – Table CM.World Bank.WDI: Social: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes. It is calculated by adjusting to a standard population age-structure.;International Diabetes Federation, Diabetes Atlas.;Weighted average;

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of this chronic condition, particularly in the aging population. According to the International Diabetes Federation, approximately 463 million adults were living with diabetes in 2019, with this number projected to increase to 700 million by 2045. The geriatric population, which is disproportionately affected by Type 2 Diabetes, is expanding rapidly, with the number of people aged 65 and above expected to double by 2050. Despite this growing demand, there remains a low diagnosis rate for Type 2 Diabetes, presenting both an opportunity and a challenge for market participants. On the one hand, there is significant potential for companies to develop and market innovative diagnostic tools and treatments to improve early detection and management of the disease. On the other hand, the low diagnosis rate also highlights the need for increased public awareness and education campaigns to encourage individuals to seek testing and take preventative measures. In , the market is poised for growth due to demographic trends and the increasing prevalence of the disease. However, companies must navigate the challenge of low diagnosis rates by investing in innovative diagnostic solutions and public awareness campaigns to capitalize on this opportunity and meet the needs of this growing patient population.

What will be the Size of the Type 2 Diabetes Market during the forecast period?

Request Free SampleThe market in the US is experiencing significant growth due to the rising prevalence of the disease, particularly among young adults and adolescents. According to recent studies, an estimated 34.2 million Americans have diabetes, with Type 2 accounting for approximately 95% of cases. Factors contributing to market expansion include the increasing incidence of obesity, a known risk factor, and the aging population. Symptoms of Type 2 diabetes include increased thirst, frequent urination, blurred vision, fatigue, numbness or tingling in the hands or feet, slow-healing wounds, and neurological problems. The disease can also lead to complications such as heart disease, kidney damage, and nerve damage. Pharmaceutical companies are developing various therapeutic compounds to manage blood sugar levels, including insulin and non-insulin medications like Trulicity, Jardiance, and Tanzeum. These drugs are readily available at retail pharmacies and are essential for maintaining normal blood glucose levels and preventing complications. Additionally, the market is driven by the growing awareness of the importance of managing diabetes to prevent cardiovascular diseases and renal problems.

How is this Type 2 Diabetes Industry segmented?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. Drug ClassInsulinDPP-4 inhibitorGLP-1 receptor agonistsSGLT-2 inhibitorsOthersDistribution ChannelRetail pharmaciesHospital pharmaciesOnline pharmaciesDelivery ModeOralInjectableContinuous glucose monitoring (CGM)GeographyNorth AmericaUSCanadaEuropeFranceGermanyItalyUKAsiaChinaIndiaJapanSouth KoreaRest of World (ROW)

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.Type 2 diabetes mellitus is a chronic metabolic disorder characterized by insulin resistance and high blood glucose levels. Adolescents and young adults are among those frequently diagnosed with this condition, which can lead to complications such as numbness in hands and feet, blurred vision, and increased thirst and urination. The disease can also cause renal problems, including kidney damage and urine glucose excretion. Pharmaceutical companies are developing various therapeutic compounds to manage Type 2 diabetes. For instance, Sotagliflozin, a dual inhibitor of SGLT1 and SGLT2, is used to reduce blood glucose levels by increasing urine glucose excretion. Meglitinides, secretagogues that stimulate insulin secretion from the pancreas, are also used to improve glycemic control. Alpha-Glucosidase Inhibitors, such as Steglatro, delay the absorption of carbohydrates in the gut, thereby reducing blood glucose levels. Dipeptidyl Peptidase-4 Inhibitors, like Jardiance, help increase insulin secretion and decrease glucagon secretion, leading to improved blood sugar control. Insulin resistance is a significant factor in Type 2 diabetes, and medications like metformin, a Biguanide, help improve insulin sensitivity. Other oral medications, such as Sulfonylureas and Thiazolidinediones, also play a role in managing blood glucose levels. Maintain

This statistic displays the crude prevalence rate of diagnosed diabetes among U.S. adults in 2016, by ethnicity and diabetes type. According to the data, the prevalence rate of type II diabetes among adults of black, non-Hispanic ethnicity was 11.52 percent in 2016.

Context: Variations in the prevalence and aetiology of type 2 diabetes (T2D) across race and ethnicity may affect treatment responses. Semaglutide is a glucagon-like peptide-1 (GLP-1) analog approved for once–weekly, subcutaneous (s.c.) treatment of T2D.

Objective: To compare semaglutide efficacy and safety in race and ethnicity subgroups across the SUSTAIN trials.

Design: Post hoc analysis of data from phase 3 randomized SUSTAIN 1–5 and 7 (pooled) and SUSTAIN 6 trials.

Participants: 3,074 subjects (SUSTAIN 1–5 and 7); 1,648 subjects (SUSTAIN 6).

Interventions: Semaglutide 0.5 or 1.0 mg, placebo or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml and dulaglutide 0.75 or 1.5 mg).

Main Outcome Measures: Change in HbA_1c and body weight from baseline to week 30/40/104, other efficacy and safety endpoints.

Results: HbA_1c was reduced from baseline by 1.0–1.5%-points and 1.3–2.0%-points, and body weight by 2.3–4.7 kg and 3.6–6.1 kg with semaglutide 0.5 and 1.0 mg, respectively, across race and ethnicity subgroups. Minor changes in blood pressure and lipid profiles were observed. Adverse events (AEs) were reported in similar proportions of subjects across trials. More Asian vs other race subgroups discontinued treatment prematurely due to AEs. The most commonly reported AEs were gastrointestinal disorders.

Conclusion(s): In this SUSTAIN trials post hoc analysis, semaglutide was associated with consistent and clinically relevant reductions in HbA_1c and body weight in subjects with T2D, with minor variations in efficacy and safety outcomes associated with race or ethnicity.

Ecuador EC: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 5.550 % in 2017. Ecuador EC: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 5.550 % from Dec 2017 (Median) to 2017, with 1 observations. Ecuador EC: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Ecuador – Table EC.World Bank.WDI: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

In 2023, there were 22.4 deaths from diabetes mellitus per 100,000 people in the United States. The death rate caused by this condition has fluctuated over the past decades, reaching almost 26 deaths per 100,000 people in the early 2000s, and about 18 deaths in 1980. Prevalence of diabetes In 2022, around 8.4 percent of the adult population in the U.S. had diabetes. In total, around 38 million adults in the United States are currently living with diabetes. Of this total, the vast majority were aged 45 years and older. The states with the highest share of adults with diabetes are West Virginia, Mississippi, and Louisiana. Cure for diabetes? Researchers are helping diabetics put their Type 2 diabetes into remission, where the blood sugar levels are kept within a healthy range. For Type 1, scientists are looking for ways to prevent the immune system’s attack on beta cells, which causes diabetes. These cells, located in the pancreas, produce the insulin people need to live. As of yet, there is no cure for diabetes mellitus; however, scientists are researching ways to make diabetes harmless one day.

Diabetes prevalence (% of population ages 20 to 79) in Cameroon was reported at 5.5 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Cameroon - Diabetes prevalence (% of population ages 20 to 79) - actual values, historical data, forecasts and projections were sourced from the World Bank on April of 2025.

Estimates of percentage point change in county-level diabetes incidence between 2004 and 2012.†

Technical notes and documentation on the common data model of the project CONCEPT-DM2.

This publication corresponds to the Common Data Model (CDM) specification of the CONCEPT-DM2 project for the implementation of a federated network analysis of the healthcare pathway of type 2 diabetes, version v0.2.0.

Aims of the CONCEPT-DM2 project:

General aim: To analyse chronic care effectiveness and efficiency of care pathways in diabetes, assuming the relevance of care pathways as independent factors of health outcomes using data from real life world (RWD) from five Spanish Regional Health Systems.

Main specific aims:

To characterize the care pathways in patients with diabetes through the whole care system in terms of process indicators and pharmacologic recommendations

To compare these observed care pathways with the theoretical clinical pathways derived from the clinical practice guidelines

To assess if the adherence to clinical guidelines influence on important health outcomes, such as cardiovascular hospitalizations.

To compare the traditional analytical methods with process mining methods in terms of modeling quality, prediction performance and information provided.

Study Design: It is a population-based retrospective observational study centered on all T2D patients diagnosed in five Regional Health Services within the Spanish National Health Service. We will include all the contacts of these patients with the health services using the electronic medical record systems including Primary Care data, Specialized Care data, Hospitalizations, Urgent Care data, Pharmacy Claims, and also other registers such as the mortality and the population register.

Cohort definition: All patients with code of Type 2 Diabetes in the clinical health records

Inclusion criteria: patients that, at 2017-01-01 or during the follow-up from 2017-01-01 to 2022-12-31 had active health card (active TIS - tarjeta sanitaria activa) and code of type 2 diabetes (T2D, DM2 in spanish) in the clinical records of primary care (CIAP2 T90 in case of using CIAP code system)

Exclusion criteria:

patients with no contact with the health system from 2017-01-01 to 2022-12-31

patients that had a T1D (DM1) code opened after the T2D code during the follow-up.

Study period. From 2017-01-01 to 2022-12-31

Files included in this publication:

Datamodel_CONCEPT_DM2_diagram_v0.2.0.jpg

Common data model specification (Datamodel_CONCEPT_DM2_v.0.2.0.xlsx)

Synthetic datasets (Datamodel_CONCEPT_DM2_sample_data_v0.2.0)

sample_data1_dm_patient.csv

sample_data2_dm_param.csv

sample_data3_dm_patient.csv

sample_data4_dm_param.csv

sample_data5_dm_patient.csv

sample_data6_dm_param.csv

sample_data7_dm_param.csv

sample_data8_dm_param.csv

Datamodel_CONCEPT_DM2_explanation_v0.2.0.pptx

CHANGE-LOG from version v0.1.0 to v0.2.0.

The main changes are the following:

Missing data is now identified leaving the field empty

All ICD diagnosis given in the Datamodel refer to the root code, so that all codes and subcodes that start with the given codes need to be considered. For instance, if in the data model appears I21, then all codes I21.x should be included.

All admissions registered in the CMBD will be included to facilitate the extraction procedure (annex 8 disappears).

Three diagnosis codes and three procedure codes are now included in table dm_cmbd.

CHANGE-LOG from version v0.2.0 to v0.3.0.

The main changes are the following:

Variable 'copayment' (annex 2) change: cod 002.01 =>0; cod 002.02 =>1

Variable 'visit_service' (annex 8) change: APR refers to Primary Care and APA refers to Pathological Anatomy

Variable 'filglom' (annex 4) change: non numerical values compatible with '> 60' => 999

Around 10.5 percent of the global adult population suffered from diabetes in 2021 - by the year 2045 this number is expected to rise to over 12 percent. Diabetes, or diabetes mellitus, refers to a group of metabolic disorders that result in chronic high blood sugar levels. Diabetes can lead to serious health complications, such as cardiovascular disease, chronic kidney disease, and stroke and is now among the top ten leading causes of death worldwide.

Prevalence
Diabetes is a global problem affecting a variety of countries. China currently has the largest number of diabetics worldwide with some 141 million people suffering from the disease. However, the highest prevalence of diabetes is found among French Polynesia, Mauritius, and Kuwait. Rates of diabetes have increased in many countries in recent years, as have rates of obesity, one of the leading risk factors for the disease.

Outlook
It is predicted that diabetes will continue to be a problem in the future. Africa is expected to see a 134 percent increase in the number of diabetics in the region from 2021 to 2045, while North America and the Caribbean are expected to see an increase of 24 percent. In 2045, China is predicted to be the country with the highest number of diabetics worldwide, with the United States accounting for the fourth highest number.

It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

This data set provides de-identified population data for diabetes and hypertension comorbidity prevalence in Allegheny County. The data is provided by three managed care organizations in Allegheny County (Gateway Health Plan, Highmark Health, and UPMC) and represents their insured population for the 2015 and 2016 calendar years.

Disclaimer: Users should be cautious of using administrative claims data as a measure of disease prevalence and interpreting trends over time, as data provided were collected for purposes other than surveillance. Limitations of these data include but are not limited to: misclassification, duplicate individuals, exclusion of individuals who did not seek care in past two years and those who are: uninsured, enrolled in plans not represented in the dataset, or were not enrolled in one of the represented plans for at least 90 days.

Support for Health Equity datasets and tools provided by Amazon Web Services (AWS) through their Health Equity Initiative.

The National Diabetes Audit (NDA) and the National Paediatric Diabetes Audit (NPDA) provide a comprehensive view of diabetes care in England and Wales. They measure the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This is the second Young People with Type 2 Diabetes report (1). It aims to document the number of people with type 2 diabetes up to the age of 40 years, their patient characteristics and the diabetes care they receive. This is important because adverse diabetes and cardiovascular outcomes are more common in people who develop type 2 diabetes at an earlier age and it is thought the numbers of affected individuals are increasing (2,3).